Status:
ACTIVE_NOT_RECRUITING
Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting
Lead Sponsor:
Chiesi Italia
Collaborating Sponsors:
Gesellschaft für Therapieforschung mbH
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
TriMaximize is a non-interventional study aimed to collect prospective data from asthmatic patients under routine care, for whom their treating physician has decided to prescribe BDP/FF/G (beclomethas...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years of age;
- Patients with confirmed leading diagnosis of asthma with or without concomitant COPD;
- Physician decision to start fixed triple therapy with ICS/LABA/LAMA (BDP/FF/G) MS or HS according to its current authorised indication and current reimbursement conditions within the Italian National Health System. The treatment decision must be made independently from participation in this study and may have started within the previous 4 weeks (maximum);
- Patients willing and able to sign an informed consent for use of their pseudonymised clinical data within the present non-interventional study.
Exclusion
- Participation in an interventional clinical trial within 30 days prior to enrolment into the present non-interventional study or planned enrolment in an interventional clinical trial during the observational period.
Key Trial Info
Start Date :
April 24 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06100042
Start Date
April 24 2024
End Date
June 30 2026
Last Update
July 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U.O. Clinica Psichiatrica e SPDC. Ospedale Policlinico S. Martino - IRCCS, Genova
Genoa, Italy